How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Female Stress Urinary Incontinence Treatment Devices Market
- By Product Type: Pessaries, Urethral Inserts, Electrical Stimulation Devices, Pelvic Floor Muscle Trainers, Absorbent Products
- By Treatment Modality: Surgical Devices, Non-Surgical Devices, Minimally Invasive Devices
- By End User: Hospitals, Urology Clinics, Gynecology Clinics, Home Care Settings
- By Technology: Biofeedback Technology, Electrical Stimulation Technology, Mechanical Support Devices
- By Patient Age Group: Reproductive Age Women, Postmenopausal Women, Elderly Women
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pessaries leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Female Stress Urinary Incontinence Treatment Devices Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Treatment Modality 3
End User 4
Technology 3
Patient Age Group 3
Companies profiled
Boston Scientific Corporation
Coloplast A/S
C.R. Bard (a BD company)
Teleflex Incorporated
Cook Medical (a division of Cook Group)
Mölnlycke Health Care
Laborie Medical Technologies
Dentsply Sirona (Uroplasty)
Neomedic International
American Medical Systems (now part of Boston Scientific)
Bard Medical (now part of BD)
SurgiTel
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Coloplast A/S
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →C.R. Bard (a BD company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Teleflex Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Cook Medical (a division of Cook Group)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Mölnlycke Health Care
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Laborie Medical Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Dentsply Sirona (Uroplasty)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Neomedic International
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →American Medical Systems (now part of Boston Scientific)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bard Medical (now part of BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →SurgiTel
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Promedon
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Medi-Tate International
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,078M by 2033 · 6.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pessaries33.6
- Urethral Inserts16.7
- Electrical Stimulation Devices12.0
- Pelvic Floor Muscle Trainers14.7
- Absorbent Products23.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,663M → $2,727M · 6.4%
Europe$1,159M → $2,081M · 7.6%
Asia Pacific$1,058M → $1,542M · 4.8%
Latin America$655.2M → $949.3M · 4.7%
Middle East and Africa$504.0M → $725.2M · 4.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.032026
6.052027
6.042028
6.072029
6.072030
6.092031
6.092032
6.112033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Boston Scientific Corporation18.7
- Coloplast A/S13.1
- C.R. Bard (a BD company)8.9
- Teleflex Incorporated13.4
- Cook Medical (a division of Cook Group)5.6
- Mölnlycke Health Care12.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type16.0%
Treatment Modality24.1%
End User31.4%
Technology15.7%
Patient Age Group12.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.0
- Europe25.9
- Asia Pacific19.2
- Latin America11.8
- Middle East and Africa9.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation | 85 | 87 | 90 | 91 | 73 | 80 | 84 |
| Coloplast A/S | 81 | 84 | 87 | 84 | 70 | 72 | 80 |
| C.R. Bard (a BD company) | 78 | 80 | 84 | 82 | 75 | 87 | 81 |
| Teleflex Incorporated | 63 | 70 | 71 | 70 | 73 | 58 | 68 |
| Cook Medical (a division of Cook Group) | 70 | 62 | 65 | 67 | 69 | 72 | 68 |
| Mölnlycke Health Care | 65 | 68 | 51 | 60 | 62 | 65 | 62 |
| Laborie Medical Technologies | 57 | 59 | 42 | 40 | 44 | 53 | 49 |
| Dentsply Sirona (Uroplasty) | 47 | 49 | 46 | 58 | 35 | 41 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Boston Scientific Corporation
- Coloplast A/S
- C.R. Bard (a BD company)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Boston Scientific Corporation | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Coloplast A/S | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| C.R. Bard (a BD company) | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Teleflex Incorporated | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Cook Medical (a division of Cook Group) | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Mölnlycke Health Care | ◐ | ✓ | − | − | − | ◐ |
| Laborie Medical Technologies | ◐ | ◐ | − | − | − | − |
| Dentsply Sirona (Uroplasty) | − | ◐ | ◐ | ◐ | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Boston Scientific Corporation84
2C.R. Bard (a BD company)81
3Coloplast A/S80
4Teleflex Incorporated68
5Cook Medical (a division of Cook Group)68
6Mölnlycke Health Care62
7Laborie Medical Technologies49
8Dentsply Sirona (Uroplasty)46
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Boston Scientific CorporationColoplast A/SC.R. Bard (a BD company)
Challenger2
Strong scale, closing on the leaders.
Teleflex IncorporatedCook Medical (a division of Cook Group)
Contender1
Focused players with pockets of strength.
Mölnlycke Health Care
Niche2
Specialists in a single segment or region.
Laborie Medical TechnologiesDentsply Sirona (Uroplasty)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Female Stress Urinary Incontinence Treatment Devices Market — a $46M beachhead inside a $889M market.
Beachhead (SOM)$46Mobtainable near-term
Serviceable (SAM)$303Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Pessaries
Best fit — highest urgency & budget in Product Type.
Economic buyer80 fit
Urethral Inserts
Strong fit — clear ROI and a fast path to value.
End user64 fit
Electrical Stimulation Devices
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel30%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Female Stress Urinary Incontinence Treatment Devices Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified25%
Evaluation12%
Closed-won8%
$21.6KCAC
$119KLTV
5.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Female Stress Urinary Incontinence Treatment Devices Market is a durable-growth opportunity — $7.09B by 2033, compounding at 6.0%.
TAM · 2025$4.44Btoday
TAM · 2033$7.09Bforecast
CAGR6.0%2027–2033
Cumulative$51.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.09BTotal addressable market
SAM$2.41BServiceable available market
SOM$458MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.0% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.09BLarge & growingTAM by 2033 at 6.0% CAGR
$2.41BServiceable nowreachable with today’s model
$458MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.53BBear3.9% CAGR
$7.09BBase6.0% CAGR
$9.08BBull7.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Female Stress Urinary Incontinence Treatment Devices Market — a $6.51B market by 2033. Plan: grow share from 6.1% to 12.3%.
Market size · 2033$6.51Btotal addressable
Market CAGR3.4%2027–2033
Target share12.3%from 6.1% today
Revenue ambition$800Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.1% | 12.3% | On track |
| Revenue | $421M | $800M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 35.4% | 45.3% | Behind |
| Customer retention | 90.8% | 96.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $114M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Female Stress Urinary Incontinence Treatment Devices Market conversation — a $7.44B market you can size, segment and defend in minutes.
Market size · 2033$7.44Btotal opportunity
Growth7.0%CAGR to 2033
Addressable buyers1,014+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 2 mopayback period
$67K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Boston Scientific CorporationColoplast A/SC.R. Bard (a BD company)Teleflex IncorporatedCook Medical (a division of Cook Group)Mölnlycke Health CareLaborie Medical TechnologiesDentsply Sirona (Uroplasty)+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Female Stress Urinary Incontinence Treatment Devices Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Female Stress Urinary Incontinence Treatment Devices Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Insufflation Tubings Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportInsufflation Management System Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportGastrostomy Tubes Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportInstrument Trays Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportInstrument Tip Protector Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportMedical Sterilization Wrap Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportPharmaceutical AGVs Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportPosterior Microsurgical Instruments Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportUrology Tables Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportMedical Waste Incinerators Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportHysteroscopy and Accessories Market
Market size, share, segmentation and regional forecast.
$835M market · 2025 base year
View reportMethotrexate Sodium Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.